Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C19H24NO3.Ca |
| Molecular Weight | 668.876 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].[H][C@@]12CN(C[C@]1([H])CCCC2)C(=O)C[C@H](CC3=CC=CC=C3)C([O-])=O.[H][C@@]45CN(C[C@]4([H])CCCC5)C(=O)C[C@H](CC6=CC=CC=C6)C([O-])=O
InChI
InChIKey=PMRVFZXOCRHXFE-FMEJWYFOSA-L
InChI=1S/2C19H25NO3.Ca/c2*21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14;/h2*1-3,6-7,15-17H,4-5,8-13H2,(H,22,23);/q;;+2/p-2/t2*15-,16+,17-;/m00./s1
| Molecular Formula | C19H24NO3 |
| Molecular Weight | 314.3988 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Mitiglinide is a drug for the treatment of type 2 diabetes currently marked under tradename Glufast. Glufast® is available as the tablet for oral use, containing 5 mg or 10 mg of Mitiglinide calcium hydrate. The recommended dose is 10 mg three times daily just before each meal (within 5 minutes). Mitiglinide was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on January 29, 2004, and is currently co-marketed in Japan by Kissei and Takeda. Mitiglinide is a rapid-acting insulin secretion-stimulating agent, its belongs to the meglitinide (glinide) class of blood glucose-lowering drugs. Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. | 2001 Apr |
|
| Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs. | 2001 Feb |
|
| Insulinotropic meglitinide analogues. | 2001 Nov 17 |
|
| Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent. | 2001 Nov 23 |
|
| The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. | 2001 Nov 9 |
|
| Study of the insulinotropic effect of the novel antihyperglycemic agent KAD-1229 using HIT T15 cells, a hamster's insulinoma cell line. | 2002 |
|
| Effects of S 21403 on hormone secretion from isolated rat pancreas at different glucose concentrations. | 2002 Dec 5 |
|
| Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. | 2002 May-Jun |
|
| [Mitiglinide (KAD-1229)]. | 2002 Sep |
|
| [Structures and mechanisms for non SU insulin secretagogues]. | 2002 Sep |
|
| Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. | 2003 |
|
| [Nateglinide and mitiglinide]. | 2003 Jul |
|
| [Meglitinide analogs: new insulinotropic agents for the treatment of non-insulin dependent diabetes]. | 2003 Jun |
|
| Mitiglinide: KAD 1229, S 21403. | 2004 |
|
| [Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)]. | 2004 Apr |
|
| The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. | 2004 Dec |
|
| [Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset]. | 2004 Oct |
|
| [Synthesis and insulinotropic activity of 2-benzylidenesuccinic acid derivatives]. | 2005 Dec |
|
| [Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia]. | 2005 Dec |
|
| [Effects of mitiglinide in treatment of impaired glucose tolerance]. | 2005 Feb |
|
| [Selection of oral antidiabetic drugs]. | 2005 Feb |
|
| Characterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic beta-cells. | 2005 Nov |
|
| Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. | 2005 Sep |
|
| Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. | 2006 Apr |
|
| Determination of mitiglinide in rat plasma by high-performance liquid chromatography with UV detection. | 2006 Apr 13 |
|
| Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. | 2006 Feb |
|
| Effects of mitiglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts. | 2006 Feb 15 |
|
| [Glinide(s), sulfonylurea(s)]. | 2006 Nov |
|
| Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus. | 2007 |
|
| Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. | 2007 Feb |
|
| High-performance liquid chromatography-electrospray ionization mass spectrometry determination of mitiglinide in human plasma and its pharmacokinetics. | 2007 Feb |
|
| Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. | 2007 Jul |
|
| Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. | 2007 Jun 1 |
|
| Mitiglinide, a novel oral hypoglycemic agent, preserves the cardioprotective effect of ischemic preconditioning in isolated perfused rat hearts. | 2007 May |
|
| Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. | 2007 Nov |
|
| Liquid chromatography/electrospray ionization tandem mass spectrometry for the quantification of mitiglinide in human plasma: validation and its application to pharmacokinetic studies. | 2008 Aug |
|
| Quantitative determination of mitiglinide in human plasma by ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry. | 2008 Jun 1 |
|
| Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. | 2008 Oct |
|
| Glinide, but not sulfonylurea, can evoke insulin exocytosis by repetitive stimulation: imaging analysis of insulin exocytosis by secretagogue-induced repetitive stimulations. | 2009 |
|
| Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy. | 2009 |
|
| Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. | 2009 |
|
| Postprandial hyperglycemia as an etiological factor in vascular failure. | 2009 Apr 29 |
|
| Ca(2+) channels on the move. | 2009 Dec 29 |
|
| Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance. | 2009 Jan |
|
| Treatment with glimepiride, but not mitiglinide and short-acting insulin, resists body weight and abdominal fat reduction under dietary energy restriction. | 2009 Mar |
|
| [Design, synthesis and hypoglycemic activity of alpha-benzylsuccinic acid derivatives]. | 2009 May |
|
| Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. | 2009 May-Jun |
|
| Effect of mitiglinide on Streptozotocin-induced experimental type 2 diabetic rats: a urinary metabonomics study based on ultra-performance liquid chromatography-tandem mass spectrometry. | 2009 Nov 1 |
|
| Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. | 2009 Sep |
|
| Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. | 2010 Feb |
Patents
Sample Use Guides
The recommended dose is 10 mg three times daily just before each meal (within 5 minutes).
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:01:10 GMT 2023
by
admin
on
Sat Dec 16 05:01:10 GMT 2023
|
| Record UNII |
P5WOR98G68
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C98079
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C132050
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
PRIMARY | |||
|
SUB25644
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
PRIMARY | |||
|
5478927
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
PRIMARY | |||
|
m7566
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
PRIMARY | |||
|
P5WOR98G68
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
PRIMARY | |||
|
SUB25643
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
PRIMARY | |||
|
100000091418
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
PRIMARY | |||
|
145525-41-3
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
PRIMARY | |||
|
DTXSID90872410
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |